Category: 57825-30-6

Jorge, Ana Rita; Chernobryva, Mariya; Rigby, Stephen E. J.; Watkinson, Michael; Resmini, Marina published an article about the compound: 1-(Bromomethyl)-4-ethylbenzene( cas:57825-30-6,SMILESS:CCC1=CC=C(CBr)C=C1 ).Formula: C9H11Br. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:57825-30-6) through the article.

Recent advances in nanomaterials have identified nanogels as an excellent matrix for novel biomimetic catalysts using the mol. imprinting approach. Polymerisable Co-cyclen complexes with phosphonate and carbonate templates were prepared, fully characterized and used to obtain nanogels that show high activity and turnover with low catalytic load, compared to the free complex, in the hydrolysis of 4-nitrophenyl phosphate, a nerve agent simulant. The chem. structure of the template has an impact on the coordination geometry and oxidation state of the metal center in the polymerisable complex resulting in very significant changes in the catalytic properties of the polymeric matrix. Both pseudo-octahedral Co(III) and trigonal-bipyramidal Co(II) structures were used for the synthesis of imprinted nanogels, and the catalytic data demonstrate that: (i) the imprinted nanogels can be used in 15% load and show turnover; (ii) the structural differences in the polymeric matrixes resulting from the imprinting approach with different templates are responsible for the mol. recognition capabilities and the catalytic activity. Nanogel P1, imprinted with the carbonate template, shows > 50% higher catalytic activity than P2 imprinted with the phosphonate.

From this literature《Incorporation of Cobalt-Cyclen Complexes into Templated Nanogels Results in Enhanced Activity》,we know some information about this compound(57825-30-6)Formula: C9H11Br, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Application of 57825-30-6. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: 1-(Bromomethyl)-4-ethylbenzene, is researched, Molecular C9H11Br, CAS is 57825-30-6, about Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design. Author is Tian, Yulin; Jin, Jing; Wang, Xiaojian; Hu, Jinping; Xiao, Qiong; Zhou, Wanqi; Chen, Xiaoguang; Yin, Dali.

We have discovered a series of triazole/oxazole-containing 2-substituted 2-aminopropane-1,3-diol derivatives as potent and selective S1P1 agonists (prodrugs) based on pharmacophore-guided rational design. Most compounds showed high affinity and selectivity for S1P1 receptor. Compounds 19b, 19d and 19p displayed clear dose responsiveness in the lymphocyte reduction model when administered orally at doses of 0.3, 1.0, 3.0 mg/kg with reduced effect on heart rate. These three compounds were also identified to have favorable pharmacokinetic properties.

From this literature《Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design》,we know some information about this compound(57825-30-6)Application of 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called Synthesis and Biological Activity of Ethyl 2-(substituted benzylthio)-4-(3′-(ethoxycarbonyl)biphenyl-4-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate Derivatives, published in 2012, which mentions a compound: 57825-30-6, mainly applied to hydropyrimidine benzylthio biphenyl derivative bactericide fungicide, Electric Literature of C9H11Br.

In the present study, a new series of Et 2-(substituted benzylthio)-4-[3′-(ethoxycarbonyl)biphenyl-4-yl]-6-methyl-1,4-dihydropyrimidine-5-carboxylate derivatives (I) was synthesized. The newly synthesized compounds were characterized by 1H-NMR, mass and C, H, N analyses. All newly synthesized compounds were screened for their antibacterial (Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes and Klebsiella pneumoniae) and antifungal (Aspergillus flavus, Aspergillus fumigatus, Candida albicans, Penicillium marneffei and Trichophyton mentagrophytes) activity. The results revealed that all synthesized compounds have a significant biol. activity against the tested microorganisms. Compounds I (R = H, Br, Et, OMe, NMe2, t-Bu, NO2) exhibited good antimicrobial activity.

From this literature《Synthesis and Biological Activity of Ethyl 2-(substituted benzylthio)-4-(3′-(ethoxycarbonyl)biphenyl-4-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate Derivatives》,we know some information about this compound(57825-30-6)Electric Literature of C9H11Br, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Synthetic Route of C9H11Br. Aromatic compounds can be divided into two categories: single heterocycles and fused heterocycles. Compound: 1-(Bromomethyl)-4-ethylbenzene, is researched, Molecular C9H11Br, CAS is 57825-30-6, about Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi. Author is Oh, Sangmi; Kim, Sungbum; Kong, Sunju; Yang, Gyongseon; Lee, Nakyung; Han, Dawoon; Goo, Junghyun; Siqueira-Neto, Jair L.; Freitas-Junior, Lucio H.; Song, Rita.

A high-throughput (HTS) and high-content screening (HCS) campaign of a com. library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogs as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which were known as the causative parasites for visceral leishmaniasis and Chagas disease, resp. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds I and II showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, resp.) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, resp.) without serious cytotoxicity toward THP-1 and U2OS cell lines.

From this literature《Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi》,we know some information about this compound(57825-30-6)Synthetic Route of C9H11Br, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 57825-30-6, is researched, Molecular C9H11Br, about Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design, the main research direction is S1P1 agonist oxazole triazole preparation pharmacophore modeling structure activity; Immunomodulator; Lymphocyte; Pharmacophore; Prodrug; S1P(1) agonist.SDS of cas: 57825-30-6.

We have discovered a series of triazole/oxazole-containing 2-substituted 2-aminopropane-1,3-diol derivatives as potent and selective S1P1 agonists (prodrugs) based on pharmacophore-guided rational design. Most compounds showed high affinity and selectivity for S1P1 receptor. Compounds 19b, 19d and 19p displayed clear dose responsiveness in the lymphocyte reduction model when administered orally at doses of 0.3, 1.0, 3.0 mg/kg with reduced effect on heart rate. These three compounds were also identified to have favorable pharmacokinetic properties.

From this literature《Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design》,we know some information about this compound(57825-30-6)SDS of cas: 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Buendia, Julien; Darses, Benjamin; Dauban, Philippe published an article about the compound: 1-(Bromomethyl)-4-ethylbenzene( cas:57825-30-6,SMILESS:CCC1=CC=C(CBr)C=C1 ).Reference of 1-(Bromomethyl)-4-ethylbenzene. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:57825-30-6) through the article.

A new tandem C-N and C-C bond-forming reaction has been achieved through RhII/Pd0 catalysis. The sequence combines a catalytic C(sp3)-H nitrene insertion with a palladium-catalyzed C-C cross-coupling to afford complex nitrogenous mols., e.g., I, with very good yields and complete stereoselectivity. The sequence first involves an iodine(III) oxidant, then the in situ generated iodine(I) byproduct is used as a coupling partner. The synthetic value of iodoarenes produced in trivalent iodine reagent mediated oxidations has been demonstrated.

From this literature《Tandem catalytic C(sp3)-H amination/sila-Sonogashira-Hagihara coupling reactions with iodine reagents》,we know some information about this compound(57825-30-6)Reference of 1-(Bromomethyl)-4-ethylbenzene, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Recommanded Product: 1-(Bromomethyl)-4-ethylbenzene. The reaction of aromatic heterocyclic molecules with protons is called protonation. Aromatic heterocycles are more basic than benzene due to the participation of heteroatoms. Compound: 1-(Bromomethyl)-4-ethylbenzene, is researched, Molecular C9H11Br, CAS is 57825-30-6, about Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists. Author is Xia, Lizi; Burger, Wessel A. C.; van Veldhoven, Jacobus P. D.; Kuiper, Boaz J.; van Duijl, Tirsa T.; Lenselink, Eelke B.; Paasman, Ellen; Heitman, Laura H.; IJzerman, Adriaan P..

We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 receptor (hA3R) antagonists to determine their kinetic profiles and affinities. Many compounds showed high affinities and a diverse range of kinetic profiles. We found hA3R antagonists with very short residence time (RT) at the receptor (2.2 min for II 5) and much longer RTs (e.g., 376 min for I or 391 min for 31). Two representative antagonists (I) and (II) were tested in [35S]GTPγS binding assays, and their RTs appeared correlated to their (in)surmountable antagonism. From a kon-koff-KD kinetic map, we divided the antagonists into three subgroups, providing a possible direction for the further development of hA3R antagonists. Addnl., we performed a computational modeling study that sheds light on the crucial receptor interactions, dictating the compounds’ binding kinetics. Knowledge of target binding kinetics appears useful for developing and triaging new hA3R antagonists in the early phase of drug discovery.

Here is a brief introduction to this compound(57825-30-6)Recommanded Product: 1-(Bromomethyl)-4-ethylbenzene, if you want to know about other compounds related to this compound(57825-30-6), you can read my other articles.

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity, published in 2014-12-26, which mentions a compound: 57825-30-6, Name is 1-(Bromomethyl)-4-ethylbenzene, Molecular C9H11Br, Quality Control of 1-(Bromomethyl)-4-ethylbenzene.

A quinazolinedione-derived screening hit 2 was discovered with cellular antiviral activity against respiratory syncytial virus (CPE EC50 = 2.1 μM), moderate efficacy in reducing viral progeny (4.2 log at 10 μM), and marginal cytotoxic liability (selectivity index, SI ∼ 24). Scaffold optimization delivered analogs with improved potency and selectivity profiles. Most notable were compounds 15 and 19 (EC50 = 300-500 nM, CC50 > 50 μM, SI > 100), which significantly reduced viral titer (>400,000-fold), and several analogs were shown to block the activity of the RNA-dependent RNA-polymerase complex of RSV.

Here is a brief introduction to this compound(57825-30-6)Quality Control of 1-(Bromomethyl)-4-ethylbenzene, if you want to know about other compounds related to this compound(57825-30-6), you can read my other articles.

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14α-demethylase, published in 2009-05-31, which mentions a compound: 57825-30-6, Name is 1-(Bromomethyl)-4-ethylbenzene, Molecular C9H11Br, Related Products of 57825-30-6.

Based on the results of computational docking to the active site of the cytochrome P 450 14α-demethylase (CYP51), a series of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols I (R = H, 2-F, 2,4-Cl2, 4-MeO2C, PhO2C, etc.) as analogs of fluconazole were designed, synthesized, and evaluated as antifungal agents. The MIC80 values indicate that compounds I (R = H, 2-F, 4-Me, etc.) exhibited higher activity against nearly all fungi tested except Aspergillus fumigatus than fluconazole, while I (R = COOR1, R1 = Me, Et, iso-Pr, COOAr, etc.; Ar = Ph, 3-O2NC6H4, 4-ClC6H4, 2-MeO2CC6H4, etc.) showed no activity or only moderate activity against all fungi tested. Noticeably, the MIC value of I (R = H, 2-F, 4-Cl) is 64 times lower than that of fluconazole against Microsporum gypseum in vitro. And I (R = H, 2-F, CO2Et) showed 128 times higher activity (with the MIC80 value of 0.0039 μg/mL) than that of fluconazole against Candida albicans and also showed higher activity than that of the other pos. controls. Computational docking experiments indicated that the inhibition of CYP51 involves a coordination bond with iron of the heme group, the hydrophilic H-bonding region, the hydrophobic region, and the narrow hydrophobic cleft. In addition, the activity of the compounds would be enhanced when the side chains were shorter.

Here is a brief introduction to this compound(57825-30-6)Related Products of 57825-30-6, if you want to know about other compounds related to this compound(57825-30-6), you can read my other articles.

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 57825-30-6, is researched, Molecular C9H11Br, about Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity, the main research direction is quinazolinedione inhibitor respiration syncytial virus RNA polymerase.Name: 1-(Bromomethyl)-4-ethylbenzene.

A quinazolinedione-derived screening hit 2 was discovered with cellular antiviral activity against respiratory syncytial virus (CPE EC50 = 2.1 μM), moderate efficacy in reducing viral progeny (4.2 log at 10 μM), and marginal cytotoxic liability (selectivity index, SI ∼ 24). Scaffold optimization delivered analogs with improved potency and selectivity profiles. Most notable were compounds 15 and 19 (EC50 = 300-500 nM, CC50 > 50 μM, SI > 100), which significantly reduced viral titer (>400,000-fold), and several analogs were shown to block the activity of the RNA-dependent RNA-polymerase complex of RSV.

Here is a brief introduction to this compound(57825-30-6)Name: 1-(Bromomethyl)-4-ethylbenzene, if you want to know about other compounds related to this compound(57825-30-6), you can read my other articles.

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider